Reappraisal of liver resection as an alternative to transplantation in locally advanced hepatoblastoma: A systematic review and analysis of pooled individual patient data.
hepatoblastoma
liver tumors
transplant oncology
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
revised:
08
08
2024
received:
22
05
2024
accepted:
06
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
28
9
2024
Statut:
aheadofprint
Résumé
There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups. According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled. A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, p = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, p = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5-85.2], LR = 87.6% [80.4-95.6], p = .140; 5-year EFS: LT = 68.5% [59.3-79.1], LR = 71.1% [60.7-83.3], p = .700). Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.
Sections du résumé
BACKGROUND
BACKGROUND
There is ongoing debate regarding liver transplantation (LT) versus liver resection (LR) for locally advanced hepatoblastoma. However, comparative studies are lacking. Consequently, a significant evidence gap persists, hindering the establishment of consensus guidelines. This study aimed to compare LT and LR for locally advanced hepatoblastoma, using predefined inclusion criteria to ensure comparable intervention groups.
METHODS
METHODS
According to current Children's Oncology Group (COG) and SIOPEL (European Childhood Liver Tumour Study Group) recommendations, hepatoblastoma that requires LT evaluation was defined as either PRETEXT (PRE-Treatment EXTent of tumor) IV F+, POST-TEXT (POST-Treatment EXTent of tumor) IV, POST-TEXT P+, and/or POST-TEXT V+. A systematic literature search (Medline/Web-of-Science/Embase) was performed. Only patients who met the aforementioned criteria were included. Patient data were extracted individually and pooled.
RESULTS
RESULTS
A total of 189 patients with locally advanced hepatoblastoma from 55 studies met the specified criteria, with 111 undergoing LT and 78 LR. There were no significant differences between the two groups in age, alpha-fetoprotein (AFP), and PRETEXT stages. Local recurrence was more common after LR (14% vs. 3% in LT, p = .008), while distant recurrence was more often observed after LT (16% vs. 5% in LR, p = .035). Overall survival (OS) and event-free survival (EFS) did not differ significantly between LT and LR (5-year OS: LT = 75.3% [95% confidence interval: 66.5-85.2], LR = 87.6% [80.4-95.6], p = .140; 5-year EFS: LT = 68.5% [59.3-79.1], LR = 71.1% [60.7-83.3], p = .700).
CONCLUSION
CONCLUSIONS
Real-life data revealed that a considerable number of patients with locally advanced hepatoblastoma underwent LR. This analysis suggests that outcomes are similar and favorable for both approaches. LR can therefore be considered an effective alternative to LT in selected cases even in locally advanced hepatoblastoma.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31339Informations de copyright
© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Kastenberg ZJ, Baertschiger RM, Cuenca AG, et al. Critical elements of pediatric liver cancer surgery. Semin Pediatr Surg. 2023;32(5):151340.
Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg. 2016;25(5):265‐275.
Zsiros J, Brugieres L, Brock P, et al. Dose‐dense cisplatin‐based chemotherapy and surgery for children with high‐risk hepatoblastoma (SIOPEL‐4): a prospective, single‐arm, feasibility study. Lancet Oncol. 2013;14(9):834‐842.
Hishiki T, Matsunaga T, Sasaki F, et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol‐2: report from the JPLT. Pediatr Surg Int. 2011;27(1):1‐8. doi:10.1007/s00383‐010‐2708‐0
Czauderna P, Haeberle B, Hiyama E, et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer. 2016;52:92‐101.
MacKinlay G, Pritchard J. A common language for childhood liver tumours. Pediatr Surg Int. 1992;7:325‐326.
Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol. 2018;48(4):536‐554.
Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37(2):123‐132; quiz 249‐250.
Meyers RL, Tiao G, de Goyet JD, Superina R, Aronson DC. Hepatoblastoma state of the art: pre‐treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr. 2014;26(1):29‐36.
Trobaugh‐Lotrario AD, Meyers RL, O'Neill AF, Feusner JH. Unresectable hepatoblastoma: current perspectives. Hepat Med. 2017;9:1‐6. doi:10.2147/HMER.S89997
Lake CM, Tiao GM, Bondoc AJ. Surgical management of locally‐advanced and metastatic hepatoblastoma. Semin Pediatr Surg. 2019;28(6):150856.
Koneru B, Flye MW, Busuttil RW, et al. Liver transplantation for hepatoblastoma. The American experience. Ann Surg. 1991;213(2):118‐121.
Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL‐1 and review of the world experience. Pediatr Blood Cancer. 2004;42(1):74‐83.
de Ville de Goyet J, Meyers RL, Tiao GM, Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. Lancet Gastroenterol Hepatol. 2017;2(6):456‐462.
Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era—recommendations from the childhood liver tumour strategy group of the international society of paediatric oncology (SIOPEL). Eur J Cancer. 2005;41(7):1031‐1036.
Trobaugh‐Lotrario AD, Meyers RL, Tiao GM, Feusner JH. Pediatric liver transplantation for hepatoblastoma. Transl Gastroenterol Hepatol. 2016;1:44.
Khan AS, Brecklin B, Vachharajani N, et al. Liver transplantation for malignant primary pediatric hepatic tumors. J Am Coll Surg. 2017;225(1):103‐113.
Ezekian B, Mulvihill MS, Schroder PM, et al. Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. Pediatr Transplant. 2018;22(8):e13305.
Boster JM, Superina R, Mazariegos GV, et al. Predictors of survival following liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma: experience from the Society of Pediatric Liver Transplantation (SPLIT). Am J Transplant. 2022;22(5):1396‐1408.
Kueht M, Thompson P, Rana A, Cotton R, O'Mahony C, Goss J. Effects of an early referral system on liver transplantation for hepatoblastoma at Texas Children's Hospital. Pediatr Transplant. 2016;20(4):515‐522.
International Childhood Liver Tumors Strategy Group (SIOPEL), Czauderna P, Otte JB, Roebuck DJ. Comments on surgical treatment of locally advanced hepatoblastoma. Cancer. 2012;118(16):4092‐4093; author reply 4094‐4095.
Meyers RL, Tiao GM, Dunn SP, Central Surgical Review Committee CsOGA‐ToCwASH. Surgical management of children with locally advanced hepatoblastoma. Cancer. 2012;118(16):4090‐4091; author reply 4094‐4095.
Fuchs J, Cavdar S, Blumenstock G, et al. POST‐TEXT III and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases. Ann Surg. 2017;266(2):318‐323.
Lautz TB, Ben‐Ami T, Tantemsapya N, Gosiengfiao Y, Superina RA. Successful nontransplant resection of POST‐TEXT III and IV hepatoblastoma. Cancer. 2011;117(9):1976‐1983.
Lee WS, Grundy R, Milford DV, et al. Renal function following liver transplantation for unresectable hepatoblastoma. Pediatr Transplant. 2003;7(4):270‐276.
El‐Gendi A, Fadel S, El‐Shafei M, Shawky A. Avoiding liver transplantation in post‐treatment extent of disease III and IV hepatoblastoma. Pediatr Int. 2018;60(9):862‐868.
Uchida H, Sakamoto S, Fukuda A, et al. Surgical treatment strategy for advanced hepatoblastoma: resection vs. transplantation. Pediatr Blood Cancer. 2018;65:S490.
Meyers RL, Czauderna P, Otte JB. Surgical treatment of hepatoblastoma. Pediatr Blood Cancer. 2012;59(5):800‐808.
Meyers RL, Maibach R, Hiyama E, et al. Risk‐stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol. 2017;18(1):122‐131.
Fuchs J, Murtha‐Lemekhova A, Pfeiffenberger J, et al. Generating evidence for diagnosis and therapy of RarE LIVEr disease: the RELIVE Initiative for systematic reviews and meta‐analyses. Syst Rev. 2022;11(1):235.
Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic Review and Meta‐Analyses of individual participant data: the PRISMA‐IPD statement. JAMA. 2015;313(16):1657‐1665.
Caplan AL, Danovitch G, Shapiro M, Lavee J, Epstein M. Time for a boycott of Chinese science and medicine pertaining to organ transplantation. Lancet. 2011;378(9798):1218.
Rogers W, Robertson MP, Ballantyne A, et al. Compliance with ethical standards in the reporting of donor sources and ethics review in peer‐reviewed publications involving organ transplantation in China: a scoping review. BMJ Open. 2019;9(2):e024473.
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non‐randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712‐716.
Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60‐63.
Uchida H, Sakamoto S, Komine R, et al. Strategy for hepatoblastoma with major vascular involvement: a guide for surgical decision‐making. Surgery. 2023;173(2):457‐463.
Duarte AABCM, Lederman HM, Alves MTS, De Souza FKM. POST‐TEXT III and IV hepatoblastoma: extensive resections or liver transplantation. J Surg. 2022;7:1550. doi:10.29011/2575‐9760.001550
Hery G, Franchi‐Abella S, Habes D, et al. Initial liver transplantation for unresectable hepatoblastoma after chemotherapy. Pediatr Blood Cancer. 2011;57(7):1270‐1275.
Whitlock RS, Portuondo JI, Espinoza AF, et al. Surgical management and outcomes of patients with multifocal hepatoblastoma. J Pediatr Surg. 2023;58(9):1715‐1726.
Browne M, Sher D, Grant D, et al. Survival after liver transplantation for hepatoblastoma: a 2‐center experience. J Pediatr Surg. 2008;43(11):1973‐1981.
Umeda K, Okajima H, Kawaguchi K, et al. Prognostic and therapeutic factors influencing the clinical outcome of hepatoblastoma after liver transplantation: a single‐institute experience. Pediatr Transplant. 2018;22(2):e13113.
Martinelli J, Habes D, Majed L, et al. Long‐term outcome of liver transplantation in childhood: a study of 20‐year survivors. Am J Transplant. 2018;18(7):1680‐1689.
Baumann U, Karam V, Adam R, et al. Prognosis of children undergoing liver transplantation: a 30‐year European study. Pediatrics. 2022;150(4):e2022057424.